Other Events ·
Tiziana Life Sciences reports first three participants dosed in Phase 2a Healey ALS trial for intranasal foralumab
TLSATiziana Life Sciences Ltd
On September 28, 2026, Tiziana Life Sciences announced that the first three participants received their initial dose of intranasal foralumab in the Phase 2a Healey ALS MyMatch BANYAN clinical trial. The study evaluates the safety and tolerability of this anti-CD3 monoclonal antibody in 44 individuals with early-stage amyotrophic lateral sclerosis (ALS). Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing immunomodulation therapies.